Haematologica

Haematologica www.haematologica.org publishes novel findings in basic, clinical and translational hematology research. Impact Factor (JCR) 7.116 (7th of 76)

Haematologica/The Hematology Journal (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by a non-profit organization, the Ferrata Storti Foundation, and serves the scientific community strictly following the International Committee of Medical Journal Editors (ICMJE, www.icmje.org) recommendations on publication ethics policies for medical journals. Haematologica was founded in 1920 by Adolfo Ferrata

Landmark Paper in Hematology: the sequencing of the first cancer genome by Ley and colleagues represents the birth of pr...
05/11/2025

Landmark Paper in Hematology: the sequencing of the first cancer genome by Ley and colleagues represents the birth of precision medicine and the use of modern genomics and epigenomics to understand mutations associated with the generation of cancer cells.
https://haematologica.org/article/view/12956

What can be done for patients who relapse after CAR T-cell therapy? Read here the cases of two patients with multiple my...
28/10/2025

What can be done for patients who relapse after CAR T-cell therapy? Read here the cases of two patients with multiple myeloma who had isolated sites of soft tissue plasmacytoma relapse following CAR T-cell therapy.
https://haematologica.org/article/view/12092

No treatment guidelines are available for rare subtypes of hematologic malignancies such as acute leukemia of ambiguous ...
24/10/2025

No treatment guidelines are available for rare subtypes of hematologic malignancies such as acute leukemia of ambiguous lineage. Therefore, especially in relapsed/refractory patients, drug-response profiling is emerging as an alternative, yet complementary, approach to genetic-based precision medicine. Read here the history of a 6-year-old male diagnosed with acute undifferentiated leukemia treated with an individualized strategy based on ex vivo drug testing.
https://haematologica.org/article/view/11955

Dexamethasone and acute myeloid leukemia (AML): new opportunities for an “old” drug. In this issue of Haematologica, the...
21/10/2025

Dexamethasone and acute myeloid leukemia (AML): new opportunities for an “old” drug. In this issue of Haematologica, the DEXAML-02 study, a prospective, multicenter, single-arm phase II trial, raises the hypothesis that the addition of dexamethasone to standard intensive induction chemotherapy may improve the outcome of patients with AML.
https://haematologica.org/article/view/11935

Twins and germline and somatic genetic contributions to many pediatric cancers. A new study shows that first-born twins ...
18/10/2025

Twins and germline and somatic genetic contributions to many pediatric cancers. A new study shows that first-born twins have a higher risk of acute leukemia, but concordance between twins is lower than expected. Epigenetics may explain birth order differences. Find here the results of the new California twin cohort study.
https://haematologica.org/article/view/11901

Infections are one of the leading causes of death in patients with lower-risk myelodysplastic syndromes (LR-MDS). A stud...
16/10/2025

Infections are one of the leading causes of death in patients with lower-risk myelodysplastic syndromes (LR-MDS). A study by Houtman and colleagues investigates the prevalence of and risk factors for infections and infection-related deaths in a large real-world study of LR-MDS.
https://haematologica.org/article/view/12019

Older patients with classical Hodgkin lymphoma have lower tolerance and inferior outcomes after standard chemotherapy re...
13/10/2025

Older patients with classical Hodgkin lymphoma have lower tolerance and inferior outcomes after standard chemotherapy regimens. Find here a new simplified index for stratifying older Hodgkin lymphoma patients as fit, unfit, or frail.
https://haematologica.org/article/view/12040

In this issue of Haematologica, the new study published by Reyes-Ruiz et al. explores how to prevent immune reactions to...
11/10/2025

In this issue of Haematologica, the new study published by Reyes-Ruiz et al. explores how to prevent immune reactions to therapeutic factor VIII (FVIII) in hemophilia A by using transplacental delivery of engineered Fc‑fused FVIII fragments or peptides.
https://haematologica.org/article/view/11978

Spotlight Review: key studies, potential impact and current limitations of the first specifically targeting ABL myristoy...
09/10/2025

Spotlight Review: key studies, potential impact and current limitations of the first specifically targeting ABL myristoyl pocket (STAMP) inhibitor, asciminib, in chronic myeloid leukemia and in other leukemias in which ABL1 or ABL2 is the key target.
https://haematologica.org/article/view/12134

Read here the new review on types, prevalence, and potential prognostic impact of therapy-related mutational signatures ...
06/10/2025

Read here the new review on types, prevalence, and potential prognostic impact of therapy-related mutational signatures in acute lymphoblastic leukemia, focusing on mechanisms of thiopurine cytotoxicity and mutagenicity.
https://haematologica.org/article/view/12064

Landmark Paper in Hematology: the FAB classification system of acute myeloid leukemia (AML), published in 1976 in the Br...
04/10/2025

Landmark Paper in Hematology: the FAB classification system of acute myeloid leukemia (AML), published in 1976 in the British Journal of Haematology, rapidly became the predominant system utilized. Today, although the classification of AML is mainly based on genetic data, morphology is relevant again in predicting response to treatments with the BCL2 inhibitor, venetoclax. In the dynamic field of AML, everything old is new again.
https://haematologica.org/article/view/12903

Indirizzo

Via Giuseppe Belli 4
Pavia
27100

Orario di apertura

Lunedì 09:00 - 18:00
Martedì 09:00 - 18:00
Mercoledì 09:00 - 18:00
Giovedì 09:00 - 18:00
Venerdì 09:00 - 18:00

Telefono

+39038227129

Sito Web

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando Haematologica pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Contatta Lo Studio

Invia un messaggio a Haematologica:

Scelte rapide

Promuovere

Condividi

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram